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Abstract. The collagen receptor uPARAP/Endo180, the 
product of the MRC2 gene, is a central component in the 
collagen turnover process governed by various mesenchymal 
cells. Through the endocytosis of collagen or large collagen 
fragments, this recycling receptor serves to direct basement 
membrane collagen as well as interstitial collagen to lysosomal 
degradation. This capacity, shared only with the mannose 
receptor from the same protein family, endows uPARAP/
Endo180 with a critical role in development and homeostasis, 
as well as in pathological disruptions of the extracellular matrix 
structure. Important pathological functions of uPARAP/
Endo180 have been identified in various cancers and in several 
fibrotic conditions. With a particular focus on matrix turnover 
in cancer, this review presents the necessary background for 
understanding the function of uPARAP/Endo180 at the molec-
ular and cellular level, followed by an in-depth survey of the 
available knowledge of the expression and role of this receptor 
in various types of cancer and other degenerative diseases.
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1. Introduction to collagen remodeling in health and disease
One of the hallmarks of cancer is tumor invasion and metas-
tasis. A central process in these events is the degradation of 
the tumor-surrounding extracellular matrix which is not only 
a crucial rate-limiting step for tumors to invade adjacent tissue 
but is also an important modification of the tumor microenvi-
ronment, leading to changes in its regulatory function. When 
tumors expand, the surrounding stroma undergoes constant 
remodeling and since collagen is the major component of the 
extracellular matrix, collagen synthesis and degradation is a 
key determinant for cancer invasion. However, collagen turn-
over is not only central for tumor invasion but is also a normal 
process in the healthy organism, occurring continuously at 
sites with tissue remodeling. This process is widespread in 
the body but occurs at highly different rates. For example, 
cartilage and tendons are characterized by a very slow rate of 
collagen turnover with a suggested half-life of over 100 years 
for cartilage (1,2), compared to the considerably accelerated 
rate in periodontal ligaments with a half-life of 3-23 days (3,4).
The most thoroughly characterized pathway of collagen 
turnover is the proteolytic breakdown process occurring in 
the extracellular space. The distinctive triple-helix structure 
and the ability to form large insoluble fibers makes collagen 
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resistant to most proteases (5). Nevertheless, a few specialized 
collagenases in the matrix metalloprotease family, including 
MMPs -1, -2, -8, -13-16, and the cysteine protease cathepsin k, 
are able to perform a proteolytic attack on the rigid structure 
(6-8). The degradation process is initiated by the unwinding of 
collagen fibers which exposes cleavage sites targeted by these 
specialized proteases. Their activity produces well-defined 
¼ and ¾ collagen fragments, which are subsequently cleared 
by other proteases. However, in addition to this well estab-
lished extracellular breakdown pathway, a less characterized 
intracellular process in which collagen is internalized through 
binding to collagen-specific receptors on the cell surface and 
delivered for lysosomal degradation has also been identified. In 
2000, two studies reported the cloning of uPARAP/Endo180, 
a type-1 membrane protein belonging to the mannose receptor 
family (9,10) which later turned out to be responsible for this 
process. This receptor, also referred to as Cd280 (11), is the 
product of the MRC2 gene, situated on chromosome 17q23 in 
humans (link to gene information: http://www.ncbi.nlm.nih.
gov/gene?db=gene&Cmd=detailssearch&Term=9902; human 
gene).
In this review, we summarize the features and function 
of uPARAP/Endo180 and discuss the putative role of this 
collagen receptor in various cancers and other diseases char-
acterized by dysregulation of collagen remodeling.
2. uPARAP/Endo180: an endocytic receptor for collagen
The collagen binding function of uPARAP/Endo180 was 
initially demonstrated in ligand competition experiments 
during the characterization of the receptor on cultured cells 
(9). studies with wild-type cells and cells from uPARAP/
Endo180-deficient mice, as well as cells transfected with 
uPARAP/Endo180 cdNA in vitro, revealed that this binding is 
associated with an active endocytosis machinery and that the 
receptor functions in collagen internalization (12-14). Thus, 
the bound collagen is routed through clathrin coated pits to 
the endosomal/lysosomal compartment (13) where collagen 
degradation occurs in a process dependent on cysteine prote-
ases (15). This routing of the bound ligand is governed by a 
short sequence motif in the small cytoplasmic domain of the 
receptor (Fig. 1) (16). The receptor is recycled back to the cell 
surface from the early endosomal compartment (16).
A complete survey of collagen subtypes has not been 
undertaken. However, the evidence obtained so far makes 
it likely that the binding and internalization capacity of 
uPARAP/Endo180 comprises most or all structural collagens. 
Positive binding and/or internalization data have been obtained 
for at least fibrillary collagens I, II and V and for sheet-like 
(basement membrane-type) collagen IV (12,13). Although it 
should be noted that additional roles of this receptor have also 
been studied in vitro, particularly in relation to cell migration 
(17,18), the discussion in this review will be focused on the 
function in collagen turnover.
Important preferences exist regarding the physical form 
of the internalized collagen. In the majority of studies on 
uPARAP/Endo180 and collagen, internalization has been 
demonstrated with solubilized collagens subjected to various 
means of labeling, meaning that the conformational state of 
the material is not known in detail. Furthermore, it is not 
completely clear what would be the physical size limit for 
collagen units or fragment to allow cell entry through internal-
ization by this receptor. studies in a mouse mammary tumor 
model showed the uptake of collagen to occur exclusively in 
uPARAP/Endo180-positive, fibroblast-like cells, with at least 
some of the internalized material having a fibril-like appear-
ance as judged by electron microscopy (19). On the other 
hand, most studies so far have counted against a function of 
uPARAP/Endo180 in regular phagocytosis (16), thus pointing 
to stringent size constraints for material to be internalized by 
this receptor.
Whereas the internalization of strictly native collagen 
fibrils is not easily quantified under controlled conditions, a 
stringent pattern can be achieved after manipulation with the 
collagen structure. Thus, a deliberate (heat-induced) dena-
turation of collagen leads to increased binding to uPARAP/
Endo180 and increased uptake by cells expressing the receptor 
(20). This observation is important because a similar denatur-
ation process occurs as a consequence of initial (single-site) 
proteolytic cleavage of triple helical collagen and indeed, 
the same study showed that pre-cleaved collagen displays 
increased binding and uptake, just like the heat-denatured 
material. In accordance with these findings, studies with fibro-
blasts on a native (insoluble) collagen matrix showed that the 
collagenase MT1-MMP on the cell surface is responsible for 
a pre-cleavage of collagen into defined soluble fragments that 
are then endocytosed by uPARAP/Endo180 (20). Experiments 
with cells seeded on a pre-assembled matrix with polymer-
ized collagen I and fibronectin showed that uPARAP/Endo180 
was indeed important for efficient cellular uptake of matrix 
collagen (21). However, these studies also pointed to a compli-
cated interplay between collagen, the fibronectin component, 
integrins and proteolytic (MMP-catalyzed) processes, in addi-
tion to the role uPARAP/Endo180. since these experiments 
did not allow a direct evaluation of the single events involved, 
the molecular form of collagen actually taken up by uPARAP/
Endo180 could not be established with certainty.
Obviously, the role of this receptor must be understood 
in the context of other collagen-binding proteins. several 
cell surface proteins are known to bind to structural colla-
gens, acting in diverse processes of adhesion, migration and 
signaling (reviewed in ref. 22). However, the majority of these 
proteins do not take part in endocytic processes such as those 
described above. It should be noted that a phagocytic collagen 
uptake mechanism in fibroblasts was noted at an early point 
(23). However, phagocytic uptake of collagen particles seems 
to be governed mainly by collagen-binding integrins such as 
α2β1 (24), unlike the clathrin-associated endocytosis medi-
ated by uPARAP/Endo180 which is integrin-independent 
(12,25). The role of the mannose receptor (MR) in collagen 
endocytosis is described in the following section.
3. Functional properties of uPARAP/Endo180 and related 
receptors
Cloning of the uPARAP/Endo180 cdNA (9,10,26) revealed 
that the protein is a member of the mannose receptor protein 
family, a well-characterized group of lectin-like endocytic 
receptors. This family includes four members in mammals. 
In addition to uPARAP/Endo180 itself, these are the (macro-
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phage) mannose receptor (MR), the M-type phospholipase A2 
receptor (PLA2R) and the dendritic cell receptor dEC-205. 
The avian immunoglobulin Y receptor is a bird homologue of 
PLA2R (27,28).
All of these receptors share a characteristic domain 
composition (29) (Fig. 1). They are type-1 membrane proteins 
which, from the N-terminus, are composed of a cysteine-rich 
(Cys-rich, Ricin B-like) domain, a fibronectin type-II (Fn-II) 
domain, a series of 8-10 C-type lectin-like domains (CTLds), 
a transmembrane segment and a small cytoplasmic domain.
The high degree of conservation of the domain structure, 
including the presence of a fibronectin type-II domain in all of 
the receptor family members (29), has prompted the investiga-
tion of any collagen-binding function in the other members 
of the family. It was soon realized that MR itself also has the 
capacity to bind and internalize collagen (30,31), most likely in 
a manner very similar to that of uPARAP/Endo180, although 
these receptors are mostly expressed on different cell types. 
Indeed, the expression of MR on liver sinusoidal endothelial 
cells is responsible for hepatic clearance of injected, solubi-
lized collagen (32) whereas MR on M2-like macrophages was 
shown to be active in the endocytosis of fluorescence-labeled 
collagen that was polymerized after injection under the skin of 
mice in vivo (33). A recent systematic study with transfected 
cells confirmed that uPARAP/Endo180 and MR both possess 
the capacity for collagen endocytosis but also showed that 
PLA2R and dEC-205 have no such capacity (34). It should 
be noted that this notion contradicts an early study, pointing 
to some degree of collagen binding in PLA2R (35) and to 
a recent study which led to the same conclusion although 
the difference between mock-transfected and PLA2R-
transfected cells was rather small (36). The background for 
this discrepancy remains to be determined. It is possible that 
some species-specific difference exists in this interaction 
as suggested in the last-mentioned study, or that PLA2R 
possesses an activity which is just much smaller than that of 
uPARAP/Endo180 and MR. Altogether, based on the direct 
comparison presented in the report (34), it is our interpreta-
tion that uPARAP/Endo180 and MR are the two dominant 
collagen receptors in this family.
Figure 1. The Mannose receptor family. schematic representation of the four protein family members. All of the proteins have the same over-all domain com-
position with an N-terminal signal peptide followed by a cysteine-rich domain, a fibronectin type II domain, 8-10 C-type lectin-like domains, a transmembrane 
spanning region and a small cytoplasmic tail. during evolution, the two additional carbohydrate recognition domains in dEC-2005 have most likely arisen 
through a gene duplication of domains 7 and 8 (85). The only family members that have been demonstrated to mediate collagen endocytosis are uPARAP/
Endo180 and the mannose receptor (MR) (34).
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As would be expected from the evidence obtained from 
several other collagen-binding proteins, the Fn-II domain of 
uPARAP/Endo180 plays a decisive role in collagen binding. 
Although the Fn-II domain does not appear to obtain the 
correct native protein folding when expressed alone, stable 
truncated versions of uPARAP/Endo180 can indeed be 
obtained which comprise the Fn-II domain with its two 
flanking domains (i.e., constructs representing the first three 
N-terminal domains of the receptor; Fig. 1). These protein 
constructs retain collagen binding (13,37). Even more clearly, 
the importance of the Fn-II domain has been shown by muta-
genesis studies, using cells transfected to express full-length 
receptor variants (34). These studies have shown, firstly, that 
the Fn-II domain of uPARAP/Endo180 can be interchanged 
with that from MR to still allow collagen internalization, 
whereas an interchange with Fn-II domains from PLA2R or 
dEC-205 leads to loss of this capability. secondly, a 10-amino 
acid loop within the Fn-II domain of uPARAP was found to be 
crucial for collagen binding and uptake.
An additional domain in uPARAP/Endo180 with func-
tional importance is the second lectin-like domain (CTLd-2). 
Although the receptor structure includes eight domains classi-
fied as CTLDs on the basis of sequence homology, it appears that 
only CTLd-2 has an active lectin function (38). This capacity to 
bind carbohydrate plays a role in the binding of glycosylated 
collagen types to the receptor. Whereas the major fibrillar 
collagen, collagen I, is largely devoid of glycosylation, the sheet-
like collagen IV of the basement membrane is more heavily 
glycosylated (39). It turns out that the binding of collagen IV to 
uPARAP/Endo180, while still dependent on the Fn-II domain, 
is modulated by the lectin function of CTLd-2. Conversely, in 
accordance with the collagen glycosylation difference, CTLd-2 
does not seem to be involved in the binding of collagen I (37).
In addition to the direct binding contributions of indi-
vidual domains, it has been suggested that dynamic properties 
of the inter-domain organization could be important for the 
functional properties of this receptor. Thus, studies by single-
particle electron microscopy have pointed to pH-dependent 
changes in the steric arrangement of the domains. At neutral 
pH, the protein seems to adopt a ‘bent’ conformation with 
the Fn-II domain contacting CTLd-2 (40) whereas, at low 
pH, it takes up a more open structure (41). since the receptor 
binds its ligand at the neutral pH conditions in the extracel-
lular environment while dissociation occurs in endosomal 
compartments at low-pH, this conformational change may be 
important in relation to ligand binding and release (42).
4. Role of uPARAP/Endo180 in the healthy organism
Gene knock-out studies (12,14) have shown that uPARAP-defi-
cient mice are born in the expected Mendelian ratio, are viable 
and fertile, have normal survival and that they phenotypically 
appear relatively normal, although they display an effect on 
bone growth as detailed in the following section. Even though 
the similar molecular function of uPARAP/Endo180 and MR 
may suggest a redundant function of these two receptors, mice 
with double deficiency for these two receptors likewise show 
no obvious phenotypic abnormality (43).
uPARAP/Endo180 is highly expressed in osteogenic 
tissue, and a number of reports have demonstrated a role for 
this collagen receptor in bone development and homeostasis. 
Perhaps the most striking evidence in this connection came 
from an independent study investigating a hereditary cattle 
disease known as the crooked tail syndrome (CTs). Animals 
suffering from CTs display severe abnormalities in bone 
development. Following the genetics in a particular strain of 
cattle and fine mapping of a locus associated with the disease, 
a 2-bp deletion in the open reading frame of the MRC2 gene 
coding for uPARAP/Endo180 was identified as the causative 
mutation (44). A second uPARAP/Endo180 mutation, likewise 
associated with this disease, was found in a later study (45). 
In mice, the consequence of uPARAP/Endo180 deficiency is 
less pronounced than that noted in cattle. However, uPARAP/
Endo180 knock-out mice show a small but significant reduc-
tion in the length of the long bones, both in newborn and adult 
mice (46,47) and a reduced bone mineral density in adult mice. 
Interestingly, the bone defect is strongly augmented when 
uPARAP/Endo180 deficiency is combined with deficiency for 
the collagenolytic protease, MT1-MMP (46). An increased 
effect on the growth retardation of the long bones is also noted 
in uPARAP/Endo180 - MMP-2 double deficient mice (47). 
However, in this case the augmentation is less pronounced 
than that seen in mice with combined uPARAP/Endo180 and 
MT1-MMP deficiency and an additional difference is noted 
when comparing different bone compartments. Thus, opposite 
to MT1-MMP-deficient mice, the lack of MMP-2 leads to an 
increase in the thickness of the calvarium (48,49). This effect 
is counteracted after combination with uPARAP/Endo180 
deficiency, demonstrating that uPARAP/Endo180 and MMP-2 
do not in all cases support the same degradative processes (47). 
studies in vitro have also contributed to understanding the role 
of uPARAP/Endo180 in bone homeostasis particularly in the 
context of the coupling between bone formation and resorp-
tion. Throughout life, bone is maintained by a remodeling 
system consisting of continuous bone resorption by osteoclasts 
followed by bone formation by the osteoblasts. Recently, it was 
suggested that uPARAP/Endo180 contributes to this process 
since migration of osteoblast progenitors into resorption pits 
created by osteoclasts appeared to be driven to some extent by 
interactions between residual collagen fragments, left behind 
by the osteoclasts, and the uPARAP/Endo180 receptor on 
osteoprogenitors (50).
so far, deficiency for uPARAP/Endo180 has not been 
reported in humans. However, a human polymorphism in the 
MRC2 gene, in the form of a synonymous sNP in exon 30, 
has been associated with the rate of recurrence after initially 
curative treatment of patients with early-stage head and neck 
squamous cell carcinoma (51). Furthermore, an sNP in an 
MRC2 intron, suggested to be situated in a regulatory region, 
was found to be associated with degenerative bony changes of 
the temporomandibular joint (52).
5. Tissue expression and regulation
In the healthy organism, uPARAP/Endo180 is primarily 
expressed by mesenchymal cells such as fibroblasts and 
osteogenic cells and it is present in sites showing active tissue 
remodeling, notably including developing bone (46,47, 53). This 
is in line with a comparative study performed on a number of 
cultured cell lines which also pointed to a clear preference for 
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mesenchymal expression (25). uPARAP/Endo180 is localized 
in membrane-associated clathrin-coated pits or intracellular 
endosomes and is a constitutively rapidly recycling receptor. In 
fact, at any given time the largest pool (70-90%) of uPARAP/
Endo180 can be found in intracellular cell compartments 
(16,54). Indeed, when staining for uPARAP/Endo180 by 
immunohistochemistry, the characteristic punctuated staining 
pattern is a reflection of its localization in membrane-associ-
ated pits and endosomal compartments (Figs. 2 and 5).
In the murine embryo, uPARAP/Endo180 is expressed in 
all tissues undergoing primary ossification, both through the 
intramembranous and the endochondral pathway, and the cells 
expressing uPARAP/Endo180 in these tissues are of osteoblast 
linage (26,53). The same expression pattern can be seen in 
young mice where uPARAP/Endo180 is found on osteoblasts/
osteocytes but also on chondrocytes (46,55), although it has 
been suggested that the expression by chondrocytes declines 
with age (55).
In accordance with the strong prevalence of uPARAP/
Endo180 in bone tissue of murine embryos and young mice, 
the calvaria and tibia are among the organs with the highest 
level of uPARAP/Endo180 expression also in adult mice (47). 
When investigating the expression pattern in adult bone tissue 
in more detail by immunohistochemistry, it was demonstrated 
that the uPARAP/Endo180-positive cells are the same as 
in young mice, i.e., osteoblastic lineage cells (47). A strong 
expression of the receptor in humans and mice was seen on 
the so-called bone lining cells which form a sheet covering 
the bone surface (47,50) (Fig. 3). These cells are thought to be 
important for bone remodeling (56) and therefore it seems that 
uPARAP/Endo180 is important not only for bone generation, 
but also for bone homeostasis.
In addition to the bone compartment, uPARAP/Endo180 
is expressed in several organs and tissues. In adult mice, the 
receptor has been demonstrated in a wide range of organs 
with particularly high levels in the uterus and lung (47,57) but 
with very low levels in liver, muscle and brain (47). In human 
tissue, one of the first screenings performed by northern 
blotting revealed high levels of uPARAP/Endo180 expres-
Figure 2. uPARAP/Endo180-mediated collagen endocytosis. Analysis of collagen uptake in: (A) wild-type and (B) uPARAP/Endo180 deficient mouse fibro-
blasts using confocal microscopy. Live cells were incubated with OG-collagen IV (green) to allow endocytosis, followed by fixation and cell surface staining 
(red). The punctuated green staining pattern indicates localization of intracellular collagen in endosomal/lysosomal compartments. scale bar, 20 µm. Figure 
was adapted from (15).
Figure 3. uPARAP/Endo180 expression in murine bone. Mouse femurs 
were immunostained with antibodies against uPARAP/Endo180 (78,79). 
(A) Overview showing the upper part of the femur. uPARAP/Endo180 staining is 
especially prominent in the primary spongiosa (dotted line). (B) Magnification 
of the area indicated in (A). Expression of uPARAP/Endo180 is observed in the 
layer of osteoblastic bone lining cells covering the bone surface (black arrow), 
in osteogenic cells (blue arrow) and in occasional osteocytes (open arrow). 
scale bars, 1 mm (A) and 250 µm (B).
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sion in the heart, prostate, testis, ovary, and intestine, with 
lower levels in brain, placenta, lung, kidney, pancreas, spleen, 
thymus and colon (26). Additional studies have reported 
uPARAP/Endo180 to be present on monocyte-derived skin 
macrophages (10), although the marker used (Cd14) might 
make it difficult to distinguish between different cell types 
belonging to the monocyte lineage. Furthermore, the receptor 
has been observed on human placental cells although there is 
some discrepancy regarding their lineage, where one report 
suggested endothelial cells in a subset of microvascular vessels 
(10) and another mesenchymal cells in the villous stroma (58). 
A complicated expression pattern, including several cell types, 
has been reported in human gingival epithelium (59); see 
further details below.
uPARAP/Endo180 has been shown to be expressed by a 
large panel of cultured cell lines, primarily of mesenchymal 
origin, and the level of expression has been shown to correlate 
with the ability to internalize collagen (25) (Fig. 4). studies 
in vitro also suggest that the regulation of this receptor is corre-
lated with the cellular activity in collagen metabolism. Thus, 
in isolated rat hepatic stellate cells, uPARAP/Endo180 was 
upregulated as a result of activation and transdifferentiation 
into a more myofibroblast-like morphology. This correlated 
with an increased ability to internalize collagen (60,61). A 
similar pattern in acquiring uPARAP/Endo180 expression and 
collagen internalization was seen using in vitro differentiated 
pancreatic stellate cell lines (62). The same study showed 
that addition of TGF-β to induce an EMT-like process in 
the pancreatic cancer cell lines enhanced uPARAP/Endo180 
expression and collagen internalization (62).
In other cell types, in vitro studies on the regulation of 
uPARAP/Endo180 expression have likewise been focused 
primarily on the role of TGF-β. For example, treatment of 
the breast cancer cell line MCF-7, the U87MG glioma cell 
line and two prostate cancer cell lines with TGF-β resulted 
in upregulation of the collagen receptor (63-65) and the same 
was observed when using human gingival fibroblasts where 
both uPARAP/Endo180 protein expression and mRNA levels 
increased in the presence of TGF-β (59). However, one report 
has shown the opposite effect where uPARAP/Endo180 RNA 
expression actually decreased in lung fibroblasts following 
TGF-β treatment (57). This difference between fibroblast reac-
tion to TGF-β may reflect a difference in tissue remodeling 
potential depending on their origin and tissue surroundings.
6. uPARAP/Endo180 in breast and prostate cancer
Early studies on the expression of uPARAP/Endo180 in breast 
cancer and premalignant conditions showed the receptor to 
be absent on tumor cells but strongly expressed by the tumor-
associated fibroblast-like cells in invasive breast carcinomas 
and to a limited extent by myoepithelial cells in benign lesions 
and ductal carcinoma in situ (66). Later studies showed a 
similar, restrictive expression pattern in the polyomavirus 
middle T-induced mammary tumor model in mice where 
uPARAP/Endo180 was found to be present on periductal fibro-
blast-like mesenchymal cells whereas the mammary epithelial 
cells and tumor cells were negative (19) (Fig. 5). Moreover, 
by combining uPARAP/Endo180 gene deficiency with this 
model, it was found that mice developed less tumor burden 
and increased collagen accumulation in the tumors as a result 
of defective collagen clearance by tumor-associated stromal 
cells (19). These studies pinpointed uPARAP/Endo180 as a 
stromal contributor to mammary tumor progression. However, 
Figure 4. uPARAP/Endo180 expression correlates with cellular ability to internalize collagen. A broad selection of cultured cell lines were assayed for collagen 
endocytosis in the absence (black columns) or presence (grey columns) of a blocking uPARAP/Endo180 antibody. The cell types analyzed have different 
expression of uPARAP/Endo180, shown in descending order from left to right. collagen internalization was normalized against a reference cell line (MG63). 
Figure was adapted from (25).
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Figure 5. uPARAP/Endo180 expression in malignant breast tumors. Invasive ductal (A) and lobular (B) human breast carcinomas and murine PyMT mammary 
tumors (C and D) were immunostained using uPARAP/Endo180 specific antibodies against human and mouse uPARAP/Endo180, respectively. (A and B) 
Expression of uPARAP/Endo180 is only detected in stromal cells (st) whereas the cancer cells (Ca) are negative. The punctuated perinuclear (B, black arrow) 
and granulated cytoplasmic (B, blue arrow) staining pattern is indicative of the localization of uPARAP/Endo180 in intracellular vesicular compartments, 
including endosomes. scale bars, 50 µm (A) and 25 µm (B). (C and d) uPARAP/Endo180 expression in: (C) mammary intraepithelial neoplasia of a 5-week-old 
female PymT mouse and (d) advanced mammary carcinoma in a 13-week-old female PymT mouse. As in human breast tumors, uPARAP/Endo180 is expressed 
in stromal fibroblast-like mesenchymal cells (arrows), but absent in mammary tumor cells (asterisks). Scale bars, 50 µm (C and D). (A and B) were adapted from 
(66); (C and d) adapted from (19).
Figure 6. Upregulation of uPARAP/Endo180 in a mouse model of liver fibrosis. Mice were treated with vehicle (A and C) or with CCl4 for 6 weeks (B and d) 
to induce liver fibrosis. Livers from these mice were then stained for uPARAP/Endo180 (78) or for fibrillar collagen with picrosirius red with fast green as 
counterstaining. The expression of uPARAP/Endo180 is seen in cells associated with fibrillar collagen accumulation and in the periportal sinusoids.  Scale 
bars, 50 µm. Figure was adapted from (79).
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studies on a large number of human breast cancers revealed 
a small subset (3-6%) of breast tumors in which the tumor 
cells were uPARAP/Endo180-positive (63). These samples 
belonged to a hormone triple-negative subtype of breast 
carcinomas with basal- (myoepithelium-) like characteristics. 
It was hypothesized that, in some tumors, tumor cells might 
acquire uPARAP/Endo180 expression, e.g., after stimulation 
with TGF-β, and that this might play a role in invasive tumor 
growth. When human MCF-7 breast tumor cells, which are 
initially uPARAP/Endo180 negative, were transfected to 
express this receptor and grown in nude mice, they displayed 
increased tumor growth and enhanced collagen turn-over, rela-
tive to mock-transfected cells (63). A recent study has proposed 
uPARAP/Endo180 as a potential marker for metastatic breast 
cancer. In this report, uPARAP/Endo180 immunoreactivity 
was observed in patient plasma samples, ascribed to protein 
shedding. Quantification of immunoreactivity by western blot-
ting indicated higher levels of uPARAP/Endo180 in recurrent 
(metastatic) breast cancer patients as compared with patients 
with early (localized) breast cancer (67).
The expression and the possible prognostic significance 
of uPARAP/Endo180 has also been studied in prostate cancer 
(68-70). It was found that uPARAP/Endo180 was increas-
ingly expressed in clinical high-risk group tumors and that 
the expression was negatively correlated with survival. The 
receptor was reported to be expressed in stromal as well as 
tumor cells, although the use of tissue microarray (TMA) 
material in the major part of these studies makes it difficult 
to quantitatively evaluate the cellular composition of these 
samples.
7. uPARAP/Endo180 in glioma
Glioma originates from the glial cells in the brain and accounts 
for about a third of all primary brain cancers. It is divided 
into four main types where glioblastoma multiforme (GBM) 
has the worst prognosis with a median survival of 15 months 
despite aggressive treatment (71). The tumors are highly 
invasive, probably being caused in part by the increased inter-
action and degradation of the ECM which promotes migration 
of the tumor cells (72). The collagen content in the brain 
mainly consists of collagen IV, which is found on basement 
membrane surrounding vascular endothelial cells. Although 
there are limited amounts of collagen in the normal brain, 
this type of collagen, together with other ECM components 
such as laminin and fibronectin, is upregulated in gliomas due 
to increased microvasculature (73). Additionally, it has been 
shown that fibrillary collagen type I is deposited within GBM 
tumors (65). Interestingly, in an in silico analysis of available 
gene expression data, uPARAP/Endo180 was shown to be 
highly upregulated in glioblastomas (grade IV) compared to 
lower grade gliomas (grade II) (65). Upregulation of uPARAP/
Endo180 was also seen in a different study where the results 
were based on a QT-PCR analysis on a cdNA panel from 
normal and GBM brain tissue (74). These findings have been 
confirmed at the protein level by immunohistochemistry in 
both whole tissue and tissue micro arrays where 80-100% of 
GBM samples analysed were positive for uPARAP/Endo180 
(65). Also, in agreement with previous studies, suggesting 
a preference for uPARAP/Endo180 expression on cells of 
mesenchymal origin, uPARAP/Endo180 was found to be 
more associated with the mesenchymal subclass of high-grade 
gliomas compared to proneural and proliferative subgroups 
(65).
The expression and function of uPARAP/Endo180 has 
also been investigated in glioma cell lines. The receptor is 
expressed by several glioma-derived cell lines and down-
regulation of uPARAP/Endo180 expression has been shown to 
reduce their migratory and collagen-invasive capacity in vitro, 
suggesting an active participation of uPARAP/Endo180 in 
glioma cell invasion (65,74). Therefore, considering the low 
expression level of uPARAP/Endo180 in normal brain tissue, 
the fact that it is highly upregulated in GBM and appears 
to have a role in tumor cell migration makes it a promising 
therapeutic target.
8. uPARAP/Endo180 in bone cancer
The most common bone cancers occur as the result of meta-
static spread from tumors in other organs, such as breast, lung 
or prostate carcinomas. When metastatic tumor cells spread 
to the bones and form secondary tumors, the result on the 
bone matrix is often a shift in bone homeostasis favoring bone 
degradation. This is hypothesized to be due to a secondary 
effect of tumor cell growth through increased osteoclast 
activity. The model is termed the ‘vicious cycle’ whereby 
tumor cells, through release of cytokines and growth factors 
activate osteoblasts which in turn secrete an osteoclast acti-
vating factor known as RANkL. Increased activity of the 
osteoclasts result in release of calcium and growth factors 
from the bone matrix which in turn stimulate tumor growth, 
thus augmenting the cycle (75). The role of uPARAP/Endo180 
in this setting is not clear but one study has reported that 
upon co-culture with osteoblasts, uPARAP/Endo180 was 
upregulated on prostate cancer cell lines while simultane-
ously expression on osteoblasts was found to decrease (64). 
In this cell culture system, uPARAP/Endo180 expression on 
osteoblasts facilitated deposition of collagen type I rather than 
degradation but the co-culture with tumor cells suppressed 
this function. Further studies on the co-culture system pointed 
to a dysregulated TGFβ1 signaling being responsible for 
these regulatory events (64). Another link between uPARAP/
Endo180 and metastatic bone cancer was found in the above-
mentioned study on uPARAP/Endo180 in the plasma of breast 
cancer patients, where the metastatic group included patients 
with bone metastases (67).
9. uPARAP/Endo180 in other cancers
An early report, focused on endothelial gene products pref-
erentially expressed in tumors, employed differential gene 
expression analysis with isolated endothelial cell material from 
malignant versus normal colorectal tissue. This study identified 
uPARAP/Endo180 among the 25 mostly elevated transcripts 
in the tumor vessels (76). However, although considerable care 
was taken to obtain pure cell populations for comparison in 
this study, it is difficult to judge whether this is actually a proof 
of endothelial upregulation because most subsequent studies 
on cancer-associated expression of this receptor have led to 
receptor identification on cell types other than the endothelium 
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(see above). An upregulation of uPARAP/Endo180 has been 
shown in hepatocellular carcinoma where a higher expression 
of the receptor was correlated with a poor prognosis (77). In 
addition, an upregulation of the receptor has been observed in 
the stromal compartment of several types of head-and-neck 
cancers, relative to the surrounding tissue (78). Furthermore, 
in this study expression was found to be most prominent in 
poorly differentiated tumors.
10. Expression and role of uPARAP/Endo180 in other 
pathological conditions
since uPARAP/Endo180 is involved in events related to collagen 
remodeling, there has been a clear rationale to investigate its 
influence in disorders characterized by dysfunctional collagen 
turnover. Fibrosis can occur in several organs in the body 
and includes a buildup of connective tissue matrix, primarily 
collagen, in response to tissue damage or due to an underlying 
genetic defect. In human liver cirrhosis, i.e., the end-stage of 
liver fibrosis, a strong, localized upregulation of uPARAP/
Endo180 was observed in fibroblast-like cells (79). Using a 
mouse model for liver fibrosis, induced by injection of CCl4, 
a similar upregulation was observed (Fig. 6). Furthermore, 
when uPARAP/Endo180-deficient mice were studied using the 
same model, fibrosis was worsened with increased collagen 
accumulation, relative to littermate wild-type mice (79). 
This points to a protective role of uPARAP/Endo180 in this 
condition, completely in line with the function in collagen 
clearance. Chronic kidney disease (Ckd) is caused in part 
by defective tissue remodeling of the tubules resulting in 
accumulation of interstitial collagens. In a mouse model for 
Ckd, induced by unilateral ureteral obstruction, uPARAP/
Endo180 deficiency was shown to give rise to aggravated renal 
fibrosis with increased collagen content and reduced collagen 
turnover (80), suggesting a function of the receptor similar to 
that found in liver fibrosis. The role of uPARAP/Endo180 in 
lung fibrosis has also been studied. Using a mouse model for 
lung fibrosis induced by bleomycin, a decrease in uPARAP/
Endo180 expression following bleomycin administration was 
demonstrated. When challenging uPARAP/Endo180-deficient 
mice with bleomycin, the collagen accumulation was larger 
and the increase in lung permeability was smaller compared 
to wild-type mice, indicating a role for uPARAP/Endo180 also 
in matrix remodeling following lung injury (57).
Wound healing and the associated scar formation and 
subsequent resolution are complicated processes that require 
an intricate balance between collagen synthesis and degrada-
tion. some tissues, like the mucosal gingiva, have the ability 
of faster wound healing with less scarring, i.e., less collagen 
deposition, compared to other tissues, which makes it relevant 
to study the molecular components involved in collagen 
turnover in this situation. Thus, the expression of uPARAP/
Endo180 has been studied in biopsies collected from normal 
and wounded human gingiva (59). In contrast to localization 
studies in most other tissues, this report pointed to expression 
of the receptor in a very broad range of cell types, including 
epithelial cells in addition to several cell populations in the 
connective tissue, and with an upregulation of expression 
on the migrating keratinocytes after the wound was made. 
Although it was suggested that various particular properties of 
the gingival epithelium may lead to a unique ability to express 
uPARAP/Endo180 (59), the use of immunofluorescence for 
detection made it difficult to evaluate the strength of the 
specific signal obtained in these tissues. During skin wound 
healing in mice, uPARAP/Endo180 expression was also seen 
to be upregulated and a delayed response in re-epithelializa-
tion was noted in mice deficient for uPARAP/Endo180 (81). 
However, deficiency for uPARAP/Endo180 did not affect the 
time course of the macroscopic process of wound closure and 
there was no difference in collagen content in wounds from 
wild-type and uPARAP/Endo180-deficient mice. The authors 
suggested the latter observation to reflect that other, compen-
satory mechanisms are in play in the skin (81).
Collagen is also abundant in human skin and during 
UV-induced aging of the skin, also known as photoaging, 
collagen integrity is lost. In more severe cases, photoaging 
can lead to development of actinic keratoses and ultimately 
squamous cell carcinoma (82). By comparing sun-exposed and 
sun-protected areas of the skin from patients diagnosed with 
early photoaging, it was demonstrated that uPARAP/Endo180 
was downregulated in the sun-damaged skin areas and that 
collagen fragments were accumulated in the same locations 
(83). Although this result was based on a comparison of skin 
surfaces from different parts of the body, the same study also 
demonstrated an acute downregulation of uPARAP/Endo180 
after experimental, short-term UV-irradiation of human skin. 
Furthermore, using an in vitro approach it was demonstrated 
that UV-exposed human dermal fibroblasts had a reduced 
expression of uPARAP/Endo180, as well as a reduced capacity 
for collagen internalization (83). A downregulation of uPARAP/
Endo180 by UV-irradiation of human dermal fibroblasts was 
also seen in another study which, furthermore, demonstrated 
that the drug all trans retinoic acid (ATRA) could serve to 
reverse the effect on uPARAP/Endo180 expression (84). The 
authors suggested that, through this effect, ATRA might be 
useful in stimulating endocytic collagen internalization which 
might in turn contribute to reduce the symptoms associated 
with photoaging.
11. Conclusions and perspectives
The discovery of uPARAP/Endo180 as an endocytic collagen 
receptor has led to the delineation of a novel intracellular 
pathway of matrix breakdown. This pathway both comple-
ments and acts in concert with the well-established function 
of matrix-degrading extracellular proteases. In spite of the 
requirement for certain proteolytic events in conjunction with 
the endocytic mechanism, the action of uPARAP/Endo180 is 
in some cases rate limiting with respect to extracellular matrix 
turnover in vivo. This is reflected by phenotypic abnormali-
ties in bone growth upon uPARAP/Endo180 deficiency, by 
protective functions in conjunction with the excessive build-up 
of extracellular matrix in fibrosis and by active pathological 
functions in the matrix breakdown processes associated with 
cancer invasion. since inactivation of uPARAP/Endo180 
would probably be well tolerated in the adult organism, the 
degradative function of this receptor makes it an interesting 
target for anti-invasive cancer therapy and treatment of other 
degenerative diseases. To pursue this possibility, important 
questions to be answered will include the details of the 
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receptor's expression pattern in various cancers, an improved 
understanding of its functional redundancy and interplay with 
other degradation mechanisms and the result of experimental 
targeting in mouse models. such studies may open the way 
for a whole new concept of treatment in matrix degenerative 
disease.
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